inVentiv, Median strategic alliance brings biomarker imaging to clinical trials

By Melissa Fassbender contact

- Last updated on GMT

Median Technologies and inVentiv Health have announced a strategic alliance to provide medical image analysis and management services for oncology clinical trials. (Image: iStock/selvanegra)
Median Technologies and inVentiv Health have announced a strategic alliance to provide medical image analysis and management services for oncology clinical trials. (Image: iStock/selvanegra)
Median Technologies will provide inVentiv Health clients with various integrated imaging services to support clients at all stages of development.

Anne Pilling, SVP, Global Project Management of inVentiv Health told Outsourcing-Pharma.com the strategic alliance will provide its customers with “the most advanced imaging biomarkers, at a time when 73% of cancer compounds in clinical trials involve biomarkers in their research and development​ design.”

inVentiv Health clients will gain access to the imaging solutions and services provider’s technology for early- to late-stage oncology trials.

No matter where our clients are in development, we’ll be able to provide support​,” said Pilling.

Early-stage clients will have access to integrated imaging services to access imaging biomarkers. For late-stage clients, Median’s management services technology will provide data integrity, reliability, and transparency.

Our clients are increasingly looking to us to provide them with innovative solutions to increase the efficiency of and accelerate the clinical trial process​,” explained Pilling.

The measurement of imaging biomarkers is a critical component of oncology research and demand for an improved methodology is high," ​she added.

"We believe that Median’s technology offers a smarter solution that will be welcomed by our oncology clients.​”

Related news

Show more

Related products

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers